Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 1 August 2026.
Announcements
5,263
Total raised
£158B
disclosed amounts
Parkwalk led the series A round with participation from life science investors and angels to fund international expansion and senior hires.
"There is a clear market need for high-quality protein reagents, especially for applications in stem cell biology and organoid research. Qkine has both a compelling technology to meet this need and a highly experienced management team to drive the growth of the business."
The investment round was led by Parkwalk Advisors and Foresight Williams Technology EIS Fund.
"The energy efficiency of many products could be greatly improved if they incorporated gas and flow sensors, but companies are unable to do so due to cost, size, or manufacturing constraints. Our vision is to bring flow- and gas-sensing technologies to all these products. This funding round helps us to scale up and bring our vision to reality."
The Danish workspace management startup has raised £3.2m led by Firstminute Capital to launch its operations in London.
"COVID-19 has changed the office space as we know it. As lockdown eases, it will be more important than ever for office environments to offer something compelling enough to compete with the benefits of working from home. Such services – that help build a strong office culture and a more productive work environment – are the types of services that Good Monday’s marketplace unlocks,"
The funding round was led by the Development Bank of Wales to support the development of data science and AI solutions in agri-tech.
"We are delighted to be working with the Development Bank of Wales who were always our preferred key strategic partner for the company and our plans in Wales. Wales is a world leader in both farming and technology. We aim to bridge both of those skills to create innovation in the food supply chain both domestically and internationally."
Novo Holdings led the financing round to support portfolio expansion and international growth.
"Through its impressive track record to date, Exscientia has demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. Novo Holdings’ investment underscores our interest in supporting technology companies that enable life science research and innovation, and our commitment to this area. We see significant opportunity for the company to further grow its participation in the drug discovery ecosystem and are excited to work with the Exscientia team in realising this vision."
